| scholarly article | Q13442814 |
| P50 | author | Adam Goodwill | Q56535651 |
| Johnathan D Tune | Q77481052 | ||
| Kieren J Mather | Q90465787 | ||
| Eli D Casalini | Q117266924 | ||
| Zachary C Berwick | Q117266925 | ||
| Steven P Moberly | Q117266926 | ||
| P2093 | author name string | Gary D Hutchins | |
| Meredith K Owen | |||
| Mark A Green | |||
| Yen Ng | |||
| Robert V Considine | |||
| Kevin M Perry | |||
| Robin L Chisholm | |||
| P2860 | cites work | Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. | Q54627651 |
| PET imaging of oxidative metabolism abnormalities in sympathetically denervated canine myocardium | Q77729118 | ||
| Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure | Q79437872 | ||
| Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines | Q80542636 | ||
| Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart | Q81538720 | ||
| Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model | Q81730896 | ||
| GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice | Q85538281 | ||
| Heart disease and stroke statistics--2012 update: a report from the American Heart Association | Q29547909 | ||
| Heart of the matter: coronary dysfunction in metabolic syndrome | Q30404992 | ||
| Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury | Q33925948 | ||
| Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? | Q34207237 | ||
| The biology of incretin hormones | Q34499706 | ||
| Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy | Q34786386 | ||
| Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors | Q35098627 | ||
| Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients | Q35654597 | ||
| Equivalence of arterial and venous blood for [11C]CO2-metabolite analysis following intravenous administration of 1-[11C]acetate and 1-[11C]palmitate | Q36206257 | ||
| Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study | Q36807441 | ||
| Mechanisms of coronary dysfunction in obesity and insulin resistance | Q36871760 | ||
| Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. | Q37322877 | ||
| Myocardial fatty acid metabolism in health and disease | Q37677921 | ||
| The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update | Q37970585 | ||
| Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-1α signaling contributing to increased vulnerability in diabetic heart | Q38317335 | ||
| Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia | Q38473330 | ||
| Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. | Q38610870 | ||
| The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men | Q39513420 | ||
| Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure | Q41267217 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. | Q42357170 | ||
| A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells | Q42996825 | ||
| Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction | Q43116787 | ||
| Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes | Q43726354 | ||
| Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow | Q44044009 | ||
| The glucagon-like peptide-1 receptor--or not? | Q44489452 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women | Q44880994 | ||
| Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. | Q46334306 | ||
| Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy | Q46604606 | ||
| AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart | Q46716866 | ||
| Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts | Q46952887 | ||
| Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels | Q47620961 | ||
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. | Q51550359 | ||
| Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. | Q51610167 | ||
| Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. | Q53163778 | ||
| P433 | issue | 4 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| obesity | Q12174 | ||
| P304 | page(s) | 365 | |
| P577 | publication date | 2013-06-14 | |
| P1433 | published in | Basic Research in Cardiology | Q2453360 |
| P1476 | title | Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus | |
| P478 | volume | 108 |
| Q37611715 | Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies |
| Q33993725 | Cardiovascular and hemodynamic effects of glucagon-like peptide-1. |
| Q39106973 | Cardiovascular consequences of metabolic syndrome. |
| Q38857056 | Cardiovascular effects of anti-diabetes drugs |
| Q26823085 | Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists |
| Q90312782 | Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes |
| Q38372787 | Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study |
| Q41878782 | Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages |
| Q37510130 | GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats |
| Q38797077 | Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction |
| Q34653078 | Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. |
| Q38218639 | Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited |
| Q41853657 | Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia |
| Q49630529 | Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure? |
| Q50026330 | Liraglutide protects cardiac function in diabetic rats through the PPARα pathway |
| Q38589032 | Mechanisms for the cardiovascular effects of glucagon-like peptide-1. |
| Q35973848 | Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle |
| Q50084370 | Multiorgan, Multimodality Imaging in Cardiometabolic Disease |
| Q37468729 | Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. |
| Q34785887 | PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction |
| Q30392463 | Saturated high-fat diet-induced obesity increases adenylate cyclase of myocardial β-adrenergic system and does not compromise cardiac function |
| Q34994502 | Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes |
Search more.